Dr. Reddy’s Laboratories Limited (NYSE:RDY) to Post Q1 2026 Earnings of $1.01 Per Share, Zacks Research Forecasts

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Stock analysts at Zacks Research decreased their Q1 2026 earnings per share estimates for Dr. Reddy’s Laboratories in a report released on Wednesday, May 1st. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.01 for the quarter, down from their previous forecast of $1.02. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $3.96 per share.

RDY has been the topic of a number of other reports. Jefferies Financial Group downgraded Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research note on Thursday, January 11th. StockNews.com downgraded Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Finally, Barclays boosted their price objective on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Monday, January 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $80.00.

Dr. Reddy’s Laboratories Trading Up 0.6 %

RDY opened at $75.21 on Friday. The firm has a market capitalization of $12.55 billion, a price-to-earnings ratio of 19.84, a PEG ratio of 1.87 and a beta of 0.57. The company’s 50 day moving average price is $73.97 and its two-hundred day moving average price is $70.73. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.55 and a quick ratio of 1.90. Dr. Reddy’s Laboratories has a fifty-two week low of $53.12 and a fifty-two week high of $77.72.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Wednesday, January 31st. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.11. Dr. Reddy’s Laboratories had a net margin of 19.26% and a return on equity of 20.97%. The firm had revenue of $867.00 million for the quarter, compared to analysts’ expectations of $827.81 million.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Several institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its position in shares of Dr. Reddy’s Laboratories by 8.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 115,499 shares of the company’s stock worth $8,036,000 after buying an additional 9,414 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in Dr. Reddy’s Laboratories by 3.6% during the fourth quarter. Sequoia Financial Advisors LLC now owns 14,294 shares of the company’s stock valued at $995,000 after buying an additional 501 shares during the period. Wellington Management Group LLP increased its holdings in Dr. Reddy’s Laboratories by 40.7% during the third quarter. Wellington Management Group LLP now owns 141,154 shares of the company’s stock worth $9,439,000 after buying an additional 40,825 shares during the last quarter. Nordea Investment Management AB raised its position in Dr. Reddy’s Laboratories by 5.3% in the third quarter. Nordea Investment Management AB now owns 23,855 shares of the company’s stock worth $1,601,000 after acquiring an additional 1,196 shares during the period. Finally, Schroder Investment Management Group boosted its stake in Dr. Reddy’s Laboratories by 62.4% in the third quarter. Schroder Investment Management Group now owns 150,165 shares of the company’s stock valued at $10,042,000 after acquiring an additional 57,681 shares during the last quarter. Institutional investors own 14.02% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.